Rainbow trout (Oncorhynchus mykiss) serum contains several IGF-binding proteins (IGFBPs) that specifically bind to IGFs. The structures of these fish IGFBPs have not been determined and their physiological functions are poorly defined. In this study, we identified a 30 kDa IGFBP present in rainbow trout serum and secreted by cultured trout hepatoma cells. This IGFBP binds to IGFs but not to insulin. This IGFBP was purified to homogeneity using a three-step procedure involving Phenyl-Sepharose chromatography, IGF-I affinity chromatography and reverse-phase HPLC. Affinity cross-linking studies indicated that this IGFBP binds to IGF-I with a higher affinity than to IGF-II. N-terminal sequence analysis of the trout IGFBP suggests that it shares high sequence identity with that of human IGFBP-1 in the N-terminal region. When added to cultured fish and human cells, the trout IGFBP inhibited IGF-I-stimulated DNA synthesis and cell proliferation in a concentration-dependent manner. The inhibitory effect of the fish IGFBP was comparable to those of human IGFBP-1 and -4. These results indicate that the IGFBP molecule is structurally and functionally conserved in evolutionarily ancient vertebrate species such as bony fish.
Introduction
The insulin-like growth factors (IGFs), including IGF-I and -II, are evolutionarily ancient hormones/growth factors present in all vertebrates and are essential for normal growth and development. IGFs exert their biological actions by interacting with specific IGF receptors localized on the cell membrane. Binding of circulating peptide hormones to cell surface receptors is a common theme in endocrinology. The IGF system, however, is unique in that the IGFs in the extracellular environment are bound to members of a family of high-affinity binding proteins (IGFBPs). To date, six high-affinity IGFBPs, designated IGFBP-1 to -6, have been isolated and cloned from humans and other mammalian species (Jones & Clemmons 1995 , Rechler 1995 , Rajaram et al. 1997 . These IGF/ IGFBP complexes prolong the half-lives of IGFs and buffer the potential acute hypoglycemic effects of high concentrations of IGFs in the circulation. Locally expressed IGFBPs can control the distribution of IGF between extracellular environments and cell surface binding sites, and may regulate IGF bioactivity by modulating its interaction with the receptor (Jones & Clemmons 1995 , Rechler 1995 , Rajaram et al. 1997 . In addition to the six high-affinity IGFBPs, a number of proteins, termed IGFBP-related proteins, have been reported to bind IGFs, albeit with very low affinity (Oh et al. 1998) .
Recent studies indicate that IGFBPs are multifunctional molecules that bind IGFs and interact with other cell surface, nuclear or soluble proteins, helping to localize, activate and provide a reservoir for the IGFs (Jones & Clemmons 1995 , Rechler 1995 . The molecular basis underlying these molecular interactions, however, is not well understood. Insight into the structures of IGFBPs has been restricted to multiple sequence alignment and the available structural studies have primarily focused on identification and characterization of the IGF binding site(s) (Rajaram et al. 1997) . This lack of knowledge hampers research efforts aimed at elucidating the molecular basis of IGFBP actions and the potential therapeutic applications of IGFs/IGFBPs. While this problem can be approached by randomly mutating various amino acid residues or by deleting different portions of the IGFBP molecules, this approach is laborious and interpretation of the results can sometimes be difficult because of the potential conformational changes accompanying these random mutations and deletions. This problem can be circumvented through a phylogenetic and molecular biological approach. The IGFBPs present in different vertebrate species are the result of a mutagenesis experiment that nature has been carrying out for several hundred million years. Therefore, a comparison of the structures and functions of human IGFBPs to those of other vertebrates, in particular those of evolutionarily ancient species, such as fish, should be instructive to our efforts to define the structural basis of IGFBP actions.
Although it has been shown that fish serum contains several IGFBPs (Siharath & Bern 1993 , Duan 1997 , 1998 , Reinecke & Collet 1998 for reviews) and partial or full-length cDNA sequences are becoming available for some fish IGFBPs (Duan et al. 1999 , Gracey et al. 2001 , Maures & Duan 2001 , the biological actions of these fish IGFBPs are poorly understood due to the lack of pure, biologically active proteins. In this study, we have identified a 30 kDa IGFBP from rainbow trout (Oncorhynchus mykiss) and purified it to homogeneity. This trout IGFBP binds to IGF-I and -II but not to insulin. When added to cultured fish and human cells, the trout IGFBP inhibited IGF-I-stimulated DNA synthesis and cell proliferation.
Materials and Methods

Materials
All chemicals and reagents were purchased from Sigma Chemical Co. (St Louis, MO, USA) unless otherwise noted. Human 125 I-IGF-I was a gift from Dr Louis Underwood, University of North Carolina at Chapel Hill. The Rainbow Molecular Mass Marker, and [ 3 H] thymidine were obtained from Amersham Life Sciences (Amersham, Bucks, UK). Human IGF-I, human IGF-II, human Des(1-3) IGF-I, salmon IGF-I and human IGFBP-1 and -4 were purchased from GroPep (Adelaide, SA, Australia). Human insulin was purchased from Sigma, and salmon insulin was a gift from Dr Erika M Plisetskaya, University of Washington. Salmon growth hormone (GH), prolactin and somatolactin were purified as reported previously (Planas et al. 1992) . Fetal bovine serum (FBS), Dulbecco's minimum essential medium (DMEM), Ham's F12 medium, penicillin, streptomycin and trypsin were purchased from GIBCO BRL (Grand Island, NY, USA).
Experimental animals and serum sampling
Juvenile rainbow trout were raised in circular tanks with circulating fresh water at 15 C under simulated natural photoperiod. They were fed to satiation once daily with Oregon Moist pellets (Moore Clarke Co. Inc., La Conner, WA, USA). To determine their effects on serum IGFBP levels, purified salmon GH, prolactin, somatolactin or saline was i.p. injected into juvenile trout at the dose of 0·5 µg/g body weight. A blood sample was obtained from the caudal vein after rapid anesthesia with tricaine methanesulfonate (MS-222, 75 mg/l) solution buffered with NaHCO 3 (5 mg/l), and stored on ice up to 3 h before centrifugation at 1465 g for 10 min at 4 C. The resulting serum was stored at -80 C until analyzed.
Cell culture and conditioned medium (CM) preparation
Rainbow trout hepatoma cells (RTH-149) were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). The cells were grown to confluence in DMEM supplemented with 10% FBS at 15 C. Confluent cultures were then maintained in serum-free DMEM (SFM) after being washed three times. SFM conditioned by these cells (CM) was collected three times once every 48 h and stored at 80 C until use. Zebrafish embryonic cells (ZF-4) were obtained from ATCC. The cells were grown in a 1:1 mixture of Hams's F12 and DMEM with penicillin (100 units/ml), streptomycin (100 µg/ml) and 10% FBS at 28·5 C. The medium was changed every third day until the cells became confluent.
Western ligand blot and affinity cross-linking
To identify the forms of IGFBPs, serum or CM samples were separated by 12·5% SDS-PAGE under non-reducing conditions. After transfer to filters (Immobilon P, 0·45 µm pore size; Millipore, Bedford, MA, USA), the filters were probed with 125 I-human IGF-I and autoradiographs were obtained as described previously (Duan et al. 1996) . For affinity cross-linking, 100 µl CM were incubated with 1 10 5 c.p.m. 125 I-human IGF-I with or without competitors in 1 PBS buffer containing 0·5% BSA and 10 mM phenylmethylsulfonyl fluoride overnight at 4 C. The proteins were cross-linked for 30 min by adding dissuccinimidyl suberate to a final concentration of 2 mM. After the reaction was stopped by adding Tris-HCl buffer, the samples were separated by SDS-PAGE. The gel was fixed, dried and exposed to X-ray film for autoradiography.
Purification of the trout IGFBP
Three hundred and sixty milliliters of CM prepared from RTH-149 cells were centrifuged at 16 000 g to remove cellular debris; the salt concentration was increased to 1·0 M by adding 18 g NaCl. The pH was adjusted to 6·6 using 1 M HCl. The sample was loaded onto a PhenylSepharose column (3 4·4 cm; BioRad, Hercules, CA, USA) previously equilibrated with 50 mM NaH 2 PO 4 , 2 mM EDTA and 1·0 M NaCl (pH 6·6). After sample loading, the column was washed with the same buffer, and subsequently eluted with the elution buffer (50 mM NaH 2 PO 4 , 2 mM EDTA, 20% acetonitrile, pH 6·6) at a rate of 1 ml/min. The fractions were analyzed for IGF binding by Western ligand blot analysis. The fractions containing proteins that bound IGF-I were pooled and lyophilized to approximately 80% to remove most of the acetonitrile. The pooled sample was loaded on an IGF-I affinity chromatography column (0·75 4 cm) and eluted with 1·0 M acetic acid. The fractions that contained IGFBP(s) were further purified by reverse-phase HPLC using a Vydac C-4 HPLC column (4·6 25 cm; Hesperia, CA, USA). The major protein peak, containing the 30 kDa IGFBP, was lyophilized and reconstituted with HPLC-grade water. The amino acid composition and N-terminal sequence were determined at the University of Michigan Protein Core Facility. The amino acid composition analysis was done using an Applied Biosystems, Inc. (Foster City, CA, USA) (ABI) Model 420H, and N-terminal sequence analysis was carried out using an ABI Model 470A sequencer following standard methods (Hunkapiller et al. 1983) .
5-Bromo-2 -deoxyuridine (BrdU) immunocytochemical staining
ZF-4 cells were used to examine the effect of trout IGFBP in modulating the mitogenic activity of IGFs. These diploid cells originated from normally developing zebrafish embryos. They grow much faster than RTH-149 cells and are highly responsive to IGF stimulation (Pozios et al. 2001) . ZF-4 cells were plated onto coverslips in six-well plates and grown to confluence. After overnight serumstarvation, the cultures were exposed to 20 µM BrdU and the desired concentrations of IGF-I and/or IGFBP. Each treatment was added to duplicate cultures. After approximately 22 h, cells were washed twice with ice-cold PBS, fixed with 2·0% formaldehyde/0·2% gluteraldehyde in PBS, and permeablized with acetone/methanol (1:1). The cells were rehydrated in PBS and denatured for 1 h in 2·0 M HCl. Next, the cells were incubated in sodium tetraborate and equilibrated in PBS. The coverslips were then blocked for 2 h in 20% normal goat serum and 0·5% Triton-X followed by overnight incubation with an antiBrdU antibody (6 µg IgG/ml). After washing, the coverslips were incubated with a TRITC-linked secondary anti-mouse antibody (1:10 dilution) for 2 h. The coverslips were washed, and exposed for 0·5 h in darkness to 4,6-diamidino-2-phenylindole (DAPI) at 0·25 mg/ml. The coverslips were washed three times in PBS and mounted onto slides. Cells were counted under a Nikon E600 fluorescence microscope facilitated with the Optronics Camera System (Melville, NY, USA). For each coverslip, at least ten view fields were randomly selected and a total of approximately 2000 cells were counted. The total cell number was determined by counting DAPIstained nuclei. The results are expressed as percent of the total cells which were BrdU positive.
DNA synthesis assay
To further compare the biological activity of the trout IGFBP and mammalian IGFBPs, thymidine incorporation assays were performed as described previously (Duan & Clemmons 1998) . Briefly, human SHSY-5Y neuroblastoma cells (ATCC) were plated onto 96-well plates (Falcon, Franklin Lakes, NJ, USA) at 15 000 cells/well in DMEM supplemented with 10% FBS and incubated for 3-5 days without a medium change. After being rinsed three times with DMEM, the cultures were exposed to DMEM containing 1 µCi [ 3 H]thymidine (ICN Biochemicals, Inc., Costa Mesa, CA, USA) and the desired concentrations of IGF-I and/or IGFBP in a final volume of 200 µl. Each treatment was added to triplicate cultures. After approximately 48 h, the cells were washed twice with PBS, twice with cold 5% trichloroacetic acid for 10 min at 4 C, and solublized in 200 µl 0·1 M NaOH/1% SDS at room temperature. The solublized DNA was harvested for liquid scintillation counting. The results are expressed as the percent change from the controls.
Statistical analysis
One-way ANOVA followed the by Fisher PLSD test was used to compare differences between control and test groups using Statview (Abacus Concept, Berkeley, CA, USA). Values are means ...
Results
Identification of a 30 kDa IGFBP
Western ligand blot analysis of serum from young rainbow trout revealed the presence of three proteins with apparent molecular sizes of approximately 45, 30 and 24 kDa that bound to labeled human IGF-I (Fig. 1A) . As reported previously (Kelley et al. 1992 , Niu & Le Bail 1993 , the levels of the 45 kDa IGFBP were increased significantly after GH treatment. Prolactin and somatolactin had no such effect. Because it had a similar molecular mass to mammalian IGFBP-3 and showed a similar regulation pattern (i.e. increased by GH treatment), this protein may represent a trout homolog of mammalian IGFBP-3. The 30 and 24 kDa IGFBPs are similar to human IGFBP-1/2 and IGFBP-4 in size, but their identities cannot be definitively determined by molecular mass estimation. To identify these IGFBPs and to determine their biological actions, we sought to isolate the 30 kDa IGFBP from trout serum. The initial isolation attempts, however, were unsuccessful due to the abundance of other proteins present in the serum. Since it is known that mammalian IGFBP-1 is exclusively produced in the liver in the postnatal stage (Jones & Clemmons 1995) , we examined the possible production of this IGFBP by fish liver cells. For this, CM was collected from cultured rainbow trout hepatoma cells (RTH-149) and subjected to Western ligand blot analysis. As shown in Fig. 1B, a 30 kDa IGFBP was present. To determine the IGF binding specificity of this protein, affinity cross-linking experiments were performed. When 125 I-IGF-I was used as the ligand, a 37 kDa band was detected (Fig. 1C, lane 2) .
125 I-IGF-I was replaced by addition of unlabeled human IGF-I and -II (lanes 3 and 4) but not by human or fish insulin (lanes 5 and 6). Des(1-3) IGF-I, which has significantly reduced affinity for mammalian IGFBPs (Francis et al. 1992) , was much less efficient in competing for binding to the tracer (data not shown). These results indicate that the 30 kDa protein secreted by rainbow trout hepatoma cells is a high-affinity, specific IGFBP.
Purification and characterization of the 30 kDa IGFBP
To isolate this 30 kDa IGFBP, 360 ml CM prepared from trout hepatoma cultures were subjected to PhenylSepharose chromatography. Elution of samples from the Phenyl-Sepharose column resulted in several fractions containing proteins that bind IGF-I (as determined by Western ligand blot). These fractions were pooled and further purified by a human IGF-I affinity chromatography column. An approximately 130-fold purification was achieved at the end of the second step (Table 1) . Final purification was achieved using reverse-phase HPLC (Fig.  2A) . The 30 kDa IGFBP eluted as a single peak at 28% acetonitrile. The purified material showed a single band of 30 kDa under reducing condition (Fig. 2B ) and comigrated with human IGFBP-1. The purity of the final product, determined by SDS-PAGE followed by silver staining and N-terminal sequencing, is higher than 99%. The final yield was estimated to be 70 µg. The overall recovery was 5% (Table 1) .
To determine the ligand binding property of this IGFBP, affinity cross-linking experiments were performed. As shown in Fig. 3A , unlabeled IGF-I was very potent in competing for the tracer. Salmon IGF-I (100% identical to trout IGF-I in primary sequence (Cao et al. 1989 , Shamblott & Chen 1993 ) was equally effective in replacing the tracer (data not shown). When human IGF-I and -II were compared, unlabeled IGF-I was more effective in competing for the tracer. At concentrations higher than 125 ng/ml, IGF-I completely eliminated radiolabeled 125 I-IGF-I binding (Fig. 3A) . Unlabeled IGF-II, on the other hand, had a minimal effect at this concentration (Fig. 3B) . When the concentration was increased to 250 ng/ml, IGF-II was partially effective in competing with the 125 I-IGF-I. At the concentration of 500 ng/ml, it completely displaced the tracer. Therefore, the 30 kDa trout IGFBP binds IGF-I with higher affinity than IGF-II.
The 30 kDa IGFBP is structurally related to mammalian IGFBP
The amino acid composition and N-terminal sequence of the trout IGFBP were determined and the results are shown in Table 2 and Fig. 4 . The observed molecular mass was 30 182 20 Da. This protein is rich in leucine, glutamic acid, glycine and aspartic acid. The N-terminal amino acid sequence was KPVLAQEPIRCAPCSPEKLS. The alignment of the trout IGFBP N-terminal amino acid sequence with the corresponding region of human IGFBP-1 to -6 is shown in Fig. 4 . The N-terminus of trout IGFBP exhibits the highest sequence identity to human IGFBP-1 (60%, 9 out of 15 residues) and IGFBP-4 (56%, 9 out of 16 residues). The sequence identities with human IGFBP-2 and -6 are substantially lower (44 and 35% respectively). The lowest sequence identities are found with human IGFBP-3 and -5 (29 and 26% respectively). The sequence identities between the trout IGFBP and the IGFBP-related proteins are insignificant. These data suggest that the 30 kDa IGFBP isolated from rainbow trout is structurally related to mammalian IGFBP-1 and -4. Figure 2 (A) HPLC purification of the 30 kDa IGFBP. The IGF-affinity-column purified IGFBP was diluted and injected onto a Vydac C-4 reverse-phase HPLC column. The sample was eluted for 5 min with 100% solvent A (0·04% trifluoroacetic acid in water), followed by the indicated gradient to 100% solvent B (0·04% trifluoroacetic acid in acetonitrile) over 40 min. The flow rate was 1·0 ml/min. The 30 kDa IGFBP eluted as the major peak at 28% solvent B (arrow). (B) Silver staining of the purified protein; 0·1 g of the purified trout IGFBP was analyzed by SDS-PAGE followed by silver staining. Lane 1: pure human IGFBP-1; lane 2: HPLC-purified rainbow trout IGFBP.
The 30 kDa IGFBP inhibits IGF-I-stimulated DNA synthesis and cell proliferation
We next examined the effect of the trout IGFBP in controlling the mitogenic action of IGF-I. For this, BrdU staining experiments were carried out using cultured zebrafish embryonic cells. These diploid cells originated from normally developing zebrafish embryos. They grow much faster than RTH-149 cells and are highly responsive to IGF stimulation (Pozios et al. 2001) . BrdU staining was not detected in serum-starved cells with the exception of rare, lightly stained nuclei. Treatment of growth-arrested cells with salmon IGF-I (100 ng/ml) resulted in 1205% (P<0·01) increase in the number of BrdU-positive cells over the control. Co-incubation of salmon IGF-I with trout IGFBP at an equal molar concentration inhibited IGF-I-stimulated cell proliferation by 63% (P<0·01). This inhibitory effect was comparable to those of mammalian IGFBP-1 and -4, which were 55 and 79% inhibition respectively (P<0·01, Fig. 5 ). Neither fish nor mammalian IGFBP alone resulted in insignificant changes in the number of proliferating cells.
To further determine the biological activity of the trout IGFBP in relation to its human counterparts, thymidine incorporation assays were performed using cultured SHSY-5Y human neuroblastoma cells. Exposure of confluent human blastoma cells to human IGF-I (100 ng/ml) resulted in a 205 32% increase (P<0·05, n=3). Addition of pure human IGFBP-1 and the trout IGFBP resulted in an insignificant change in the basal DNA synthesis levels. When co-incubated with human IGF-I, both human and trout IGFBP inhibited IGF-I-stimulated DNA synthesis in a dose-dependent manner (Fig. 6 ). Human IGFBP-1 appeared to be more potent than the trout IGFBP in inhibiting IGF-I action in these human cells, although the differences were not statistically significant. These data indicate that the trout IGFBP is an inhibitor of IGF-I actions in both fish and mammalian biological systems and its growth inhibitory activity is comparable to that of its human homologs.
Discussion
In this study, we have identified and isolated a highaffinity IGFBP from rainbow trout and determined its partial sequence. To our knowledge, this is the first time a native IGFBP protein has been purified and characterized from a teleost species or any non-mammalian species. Structural, biochemical, and functional analyses indicate that: (i) this trout IGFBP is structurally related to human IGFBP-1 and -4; (ii) it has a comparable molecular size to that of human IGFBP-1; (iii) it binds to IGF-I with higher affinity than IGF-II; and (iv) it inhibits IGF-stimulated DNA synthesis and cell proliferation.
Previous studies have shown the presence of several IGFBPs with the molecular sizes of 24-25, 29-32 and Lane 8 is the negative control that received 500 ng/ml human insulin. 40-50 kDa in a number of teleost fish species, including rainbow trout (Kelley et al. 1992 , Anderson et al. 1993 , Niu & Le Bail 1993 , Fukazawa et al. 1995 , Siharath et al. 1995a ,b, Moriyama et al. 1997 , Shimizu et al. 1999 , Park et al. 2000 . The levels of these fish IGFBPs have been shown to be regulated by multiple hormonal and nutritional factors. Local production of these IGFBPs has also been demonstrated by organ cultures of various fish tissues (Fukazawa et al. 1995) . In striped bass, an additional protein with a molecular size of 80-85 kDa has been found to bind IGFs (Siharath et al. 1995b ). This protein is similar in size to a 70-75 kDa IGFBP identified in chicken serum (McMurtry et al. 1996) , which has recently been identified as vitronectin (Upton et al. 1999) . In addition, a 20 kDa IGFBP, which may represent either the proteolytic fragment of a known IGFBP or a novel IGFBP, has been detected in hypophysectomized tilapia (Park et al. 2000) . In this study, three major forms of IGFBPs, with estimated sizes of 45, 30 and 24 kDa, are found in rainbow trout serum. These are similar in size to those reported for other teleost fishes. We were unable to detect either the 'big' IGFBP or the 20 kDa IGFBP in rainbow trout serum. This is consistent with a recent study by Shimizu et al. (1999) in coho salmon, although the same report found a 70-75 kDa protein in chinook salmon serum that binds IGF-I. Of the three major IGFBPs, the 40-50 kDa IGFBP has been postulated to be fish IGFBP-3. It had a similar molecular mass to human IGFBP-3 and it showed a similar regulation pattern as mammalian IGFBP-3 (i.e. increased by GH treatment and decreased by fasting) (Kelley et al. 1992 , Niu & Le Bail 1993 , Shimizu et al. 1999 . The identities of these two low molecular mass fish IGFBPs are yet to be determined and their structures are unknown. In this study, a 30 kDa IGFBP secreted by trout hepatoma cells was isolated to homogeneity. When the purified trout IGFBP was analyzed, we found that it bound to salmon and human IGFs with high affinity but did not bind to salmon or human insulin. This suggests that this is indeed a high-affinity, specific IGFBP. Several lines of evidence suggest that this 30 kDa protein is probably a trout homolog of IGFBP-1. First, the N-terminal sequence of the trout IGFBP-1 shows the highest homology to mammalian IGFBP-1. The molecular mass of this protein is the same as that of mammalian IGFBP-1 (30 kDa). Like mammalian IGFBP-1, the trout 30 kDa IGFBP is secreted by liver cells and it preferentially binds to IGF-I over IGF-II. In mammals, the expression of the IGFBP-1 gene is strongly and acutely stimulated under catabolic conditions. Both insulindependent diabetes mellitus and starvation resulted in elevated IGFBP-1 levels in the circulation. This has been linked to the regulatory effects of insulin and glucocorticoids (see Kelley et al. 1995 for review) . This physiological regulation pattern of IGFBP-1 appears to be applicable to the 30 kDa fish IGFBP. The level of the 30 kDa fish IGFBP has been shown to be regulated by insulin (Kelley et al. 1992) . A dramatic increase in the circulating levels of a low molecular mass IGFBP has been observed in fasted striped bass (Siharath et al. 1996) . Collectively, these findings strongly indicate that the 30 kDa IGFBP isolated from rainbow trout is likely to be a trout homolog of human IGFBP-1. However, due to the limited amount of pure protein, we were only able to obtain the N-terminal sequence. Although partial sequences (deduced from cDNA sequence) of the long-jawed mudsucker and zebrafish IGFBP-1 have been reported (Gracey et al. 2001 , Maures & Duan 2001 , these partial sequences lack the N-terminal region and therefore make the sequence comparison to our trout IGFBP-1 not possible at present. Further molecular cloning studies are needed to determine the full-length structure of the trout 30 kDa IGFBP.
An intriguing finding made in this study is that despite several hundred million years of separation during vertebrate evolution, the biochemical characteristics and functionality of the trout IGFBP are highly similar to those of its human counterpart. The trout IGFBP binds to human IGF-I with an affinity that is comparable to that of the homologous fish IGF-1. In addition, human IGF-I was more efficient than IGF-II in competing for binding, suggesting that like mammalian IGFBP-1, this fish IGFBP preferentially binds to IGF-I over IGF-II. Although the partial sequence (21 residues) determined by this study contains limited information to draw a definitive conclusion on the identity of the trout IGFBP, it is nevertheless apparent that this fish IGFBP bears significant structural similarity to its mammalian counterparts in the N-terminal region. This is in agreement with our recent molecular study showing that the primary sequence of the full-length zebrafish IGFBP-2, deduced from its cDNA sequence, shares high sequence identity with human IGFBP-2 (52%) (Duan et al. 1999) .
The 30 kDa trout IGFBP isolated in this study inhibited IGF-I-stimulated cell proliferation when tested in fish as well as in human bioassay systems. It has been shown that mammalian IGFBP-1 has the capacity to both inhibit and potentiate IGF-I actions in a variety of mammalian cell culture systems. The majority of studies indicate that addition of exogenous IGFBP-1 inhibits IGF-I-stimulated cell proliferation and DNA synthesis (Jones & Clemmons 1995) . For instance, Campell & Novak (1991) showed that excess IGFBP-1 inhibited IGF-I binding to the IGF-I receptor and IGF-I-stimulated DNA synthesis in GM-63 human osteosarcoma cells, whereas receptor binding and DNA synthesis stimulated by Des(1-3) IGF-I were not inhibited. Since the IGF-I receptor mediates the biological actions of the IGFs, and because soluble IGFBP-1 binds to IGFs with higher affinity than does the IGF-I receptor, the inhibitory effects of IGFBP-1 can be rationally attributed to its competition for the ligand with cell surface receptors, particularly when IGFBP-1 is in molar excess to IGF. Previous studies have shown that human and fish IGF-Is are equally potent in stimulating the DNA synthesis of cultured zebrafish cells (Bauchat et al. 1997 , Pozios et al. 2001 . In this study, we showed that the 30 kDa trout IGFBP inhibited IGF-I-induced DNA synthesis and cell proliferation in the fish bioassay system. A similar inhibitory effect was found when this protein was added together with IGF-I to SHSY-5Y human neuroblastoma cells. These results suggest that the putative trout IGFBP-1 inhibits cell proliferation when added exogenously in cultured human, as well as fish cells. It is worthy of note that the trout IGFBP appeared to be more effective than human IGFBP-1 in inhibiting IGF actions in fish cells. Likewise, human IGFBP-1 appeared to be more potent than the trout IGFBP in inhibiting IGF-I action in human cells, although the differences were not statistically significant. These results are consistent with the idea that there may be quantitative differences in the affinities of human and fish IGF-I for fish IGFBPs (Degger et al. 1999 ).
In conclusion, we have identified and purified a 30 kDa IGFBP from rainbow trout. Structural, biochemical and functional analyses indicate this IGFBP is likely to be the fish homolog of human IGFBP-1. The finding that the IGFBP is conserved structurally and functionally in a teleost fish supports the concept that IGFBPs are a family of important growth regulatory proteins present in most, if not all, vertebrates. The availability of the pure, biologically active trout IGFBP will undoubtedly facilitate further studies on IGFBP physiology in this model teleost fish. The acquisition of the N-terminal sequence of this unique IGFBP will enable us to determine its full-length structure by molecular cloning and to elucidate the functionally important motifs of the IGFBP molecule through a comparative and molecular biological approach.
